Does the media prefer SEPN or MIRM?

In the previous week, Mirum Pharmaceuticals had 28 more articles in the media than Septerna. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat Mirum Pharmaceuticals' score of 0.11 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CGON or SEPN?

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,647.74 -$160.99M -$2.69 N/A Septerna $45.95M 38.09 -$48.88M -$0.81 N/A

Is CGON or SEPN more profitable?

Septerna has a net margin of -49.88% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -12.72% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -26.58% -25.34% Septerna -49.88% -12.72% -8.87%

Does the media refer more to CGON or SEPN?

In the previous week, CG Oncology had 22 more articles in the media than Septerna. MarketBeat recorded 29 mentions for CG Oncology and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat CG Oncology's score of 0.03 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SEPN or XENE?

In the previous week, Xenon Pharmaceuticals had 8 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 7 mentions for Septerna. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Septerna's score of 0.53 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or SEPN?

In the previous week, Dianthus Therapeutics had 28 more articles in the media than Septerna. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 7 mentions for Septerna. Dianthus Therapeutics' average media sentiment score of 0.54 beat Septerna's score of 0.53 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or SEPN?

In the previous week, Ligand Pharmaceuticals had 22 more articles in the media than Septerna. MarketBeat recorded 29 mentions for Ligand Pharmaceuticals and 7 mentions for Septerna. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Septerna's score of 0.53 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Septerna (SEPN) Competitors

$38.83 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$38.84 +0.01 (+0.03%)

As of 08/7/2026 07:34 PM Eastern

Compare

SEPN vs. MIRM, CGON, XENE, DNTH, and LGND

Should you buy Septerna stock or one of its competitors? MarketBeat compares Septerna with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Septerna include Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Xenon Pharmaceuticals (XENE), Dianthus Therapeutics (DNTH), and Ligand Pharmaceuticals (LGND). These companies are all part of the "biotechnology" industry.

How does Septerna compare to Mirum Pharmaceuticals?

Septerna (NASDAQ:SEPN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Septerna currently has a consensus target price of $45.89, indicating a potential upside of 18.18%. Mirum Pharmaceuticals has a consensus target price of $137.33, indicating a potential upside of 36.45%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A
Mirum Pharmaceuticals	$521.31M	12.54	-$23.36M	-$14.55	N/A

Septerna has a net margin of -49.88% compared to Mirum Pharmaceuticals' net margin of -139.18%. Septerna's return on equity of -12.72% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Septerna has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 28 more articles in the media than Septerna. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat Mirum Pharmaceuticals' score of 0.11 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Septerna on 8 of the 14 factors compared between the two stocks.

How does Septerna compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Septerna has a net margin of -49.88% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -12.72% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Septerna	-49.88%	-12.72%	-8.87%

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,647.74	-$160.99M	-$2.69	N/A
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A

CG Oncology presently has a consensus target price of $83.18, suggesting a potential upside of 10.76%. Septerna has a consensus target price of $45.89, suggesting a potential upside of 18.18%. Given Septerna's stronger consensus rating and higher possible upside, analysts plainly believe Septerna is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CG Oncology had 22 more articles in the media than Septerna. MarketBeat recorded 29 mentions for CG Oncology and 7 mentions for Septerna. Septerna's average media sentiment score of 0.53 beat CG Oncology's score of 0.03 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Septerna beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Septerna compare to Xenon Pharmaceuticals?

Septerna (NASDAQ:SEPN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Septerna has higher revenue and earnings than Xenon Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Septerna presently has a consensus price target of $45.89, suggesting a potential upside of 18.18%. Xenon Pharmaceuticals has a consensus price target of $77.13, suggesting a potential upside of 21.74%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Septerna has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 8 more articles in the media than Septerna. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 7 mentions for Septerna. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Septerna's score of 0.53 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Septerna on 10 of the 17 factors compared between the two stocks.

How does Septerna compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Dianthus Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

In the previous week, Dianthus Therapeutics had 28 more articles in the media than Septerna. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 7 mentions for Septerna. Dianthus Therapeutics' average media sentiment score of 0.54 beat Septerna's score of 0.53 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Septerna has a net margin of -49.88% compared to Dianthus Therapeutics' net margin of -10,096.95%. Septerna's return on equity of -12.72% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Septerna	-49.88%	-12.72%	-8.87%

Dianthus Therapeutics currently has a consensus target price of $124.27, suggesting a potential upside of 14.10%. Septerna has a consensus target price of $45.89, suggesting a potential upside of 18.18%. Given Septerna's higher probable upside, analysts clearly believe Septerna is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Septerna has higher revenue and earnings than Dianthus Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,918.95	-$162.34M	-$4.15	N/A
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A

Summary

Septerna beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Septerna compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Ligand Pharmaceuticals had 22 more articles in the media than Septerna. MarketBeat recorded 29 mentions for Ligand Pharmaceuticals and 7 mentions for Septerna. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Septerna's score of 0.53 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

Ligand Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$290.54M	20.22	$124.45M	$9.35	31.35
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A

Ligand Pharmaceuticals has a net margin of 67.88% compared to Septerna's net margin of -49.88%. Ligand Pharmaceuticals' return on equity of 20.06% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Septerna	-49.88%	-12.72%	-8.87%

Ligand Pharmaceuticals presently has a consensus target price of $336.57, indicating a potential upside of 14.81%. Septerna has a consensus target price of $45.89, indicating a potential upside of 18.18%. Given Septerna's higher probable upside, analysts clearly believe Septerna is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Septerna on 11 of the 17 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.75B	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-47.94	9.02	270.58	25.05
Price / Sales	38.09	1,289.00	658.42	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.55	17.52	11.18	6.43
Net Income	-$48.88M	-$13.25M	$3.45B	$348.10M
7 Day Performance	11.01%	4.99%	3.39%	2.66%
1 Month Performance	8.07%	-2.14%	-0.71%	-0.85%
1 Year Performance	232.16%	61.21%	77.30%	23.96%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	2.0778 of 5 stars	$38.83 flat	$45.89 +18.2%	+232.2%	$1.75B	$45.95M	N/A	N/A	Gap Up
MIRM Mirum Pharmaceuticals	2.9626 of 5 stars	$104.33 -0.2%	$143.40 +37.4%	+67.8%	$6.36B	$521.31M	N/A	140	Trending News Earnings Report Analyst Upgrade Analyst Revision
CGON CG Oncology	2.2035 of 5 stars	$71.40 +3.3%	$81.73 +14.5%	+202.2%	$6.30B	$4.04M	N/A	61	Trending News Earnings Report Analyst Forecast Analyst Revision
XENE Xenon Pharmaceuticals	2.5807 of 5 stars	$64.01 +2.8%	$77.20 +20.6%	+89.5%	$6.19B	$7.50M	N/A	210	Trending News Earnings Report Analyst Forecast Analyst Revision
DNTH Dianthus Therapeutics	2.1008 of 5 stars	$110.92 +4.6%	$117.82 +6.2%	+480.6%	$6.06B	$2.04M	N/A	80	Trending News Earnings Report Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. MIRM, CGON, XENE, DNTH, and LGND

How does Septerna compare to Mirum Pharmaceuticals?

Summary

How does Septerna compare to CG Oncology?

Summary

How does Septerna compare to Xenon Pharmaceuticals?

Summary

How does Septerna compare to Dianthus Therapeutics?

Summary

How does Septerna compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. MIRM, CGON, XENE, DNTH, and LGND

How does Septerna compare to Mirum Pharmaceuticals?

Do analysts rate SEPN or MIRM?

Which has stronger earnings & valuation, SEPN or MIRM?

Is SEPN or MIRM more profitable?

Which has more risk & volatility, SEPN or MIRM?

Does the media prefer SEPN or MIRM?

Summary

How does Septerna compare to CG Oncology?

Which has more risk and volatility, CGON or SEPN?

Is CGON or SEPN more profitable?

Which has stronger earnings and valuation, CGON or SEPN?

Do analysts rate CGON or SEPN?

Do institutionals and insiders hold more shares of CGON or SEPN?

Does the media refer more to CGON or SEPN?

Summary

How does Septerna compare to Xenon Pharmaceuticals?

Which has preferable earnings and valuation, SEPN or XENE?

Do institutionals & insiders have more ownership in SEPN or XENE?

Is SEPN or XENE more profitable?

Do analysts recommend SEPN or XENE?

Which has more risk & volatility, SEPN or XENE?

Does the media favor SEPN or XENE?

Summary

How does Septerna compare to Dianthus Therapeutics?

Which has more risk and volatility, DNTH or SEPN?

Does the media prefer DNTH or SEPN?

Do institutionals and insiders have more ownership in DNTH or SEPN?

Is DNTH or SEPN more profitable?

Do analysts recommend DNTH or SEPN?

Which has preferable valuation and earnings, DNTH or SEPN?

Summary

How does Septerna compare to Ligand Pharmaceuticals?

Does the media prefer LGND or SEPN?

Which has more risk & volatility, LGND or SEPN?

Which has stronger earnings and valuation, LGND or SEPN?

Is LGND or SEPN more profitable?

Do analysts recommend LGND or SEPN?

Do insiders & institutionals hold more shares of LGND or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools